Completed PHASE4 INTERVENTIONAL 2-arm NCT00911651

Study to Assess the Effect of Salbutamol and Ipratropium Bromide in Chronic Obstructive Pulmonary Disease (COPD) Patients

Open, Randomized, Two-Way Crossover, Pilot Study to Assess the Effect of Salbutamol in Comparison With Ipratropium Bromide on Central and Peripheral Airway Dimensions in COPD Patients

Sponsor: GlaxoSmithKline

Conditions COPD

Interventions Salbutamol ipratropium bromide

Updated 5 times since 2017 Last updated: Jun 1, 2009 Started: Jun 30, 2008 Primary completion: Jul 31, 2008 Completion: Aug 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00911651, this PHASE4 trial focuses on COPD and remains completed. Sponsored by GlaxoSmithKline, it has been updated 5 times since 2008, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Jun 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline
University Hospital, Antwerp

Data source: University Hospital, Antwerp

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Antwerp, Belgium